- Home
- SRM vs BTAI Comparison
SRM vs BTAI Comparison
Compare SRM & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRM
- BTAI
- Stock Information
- Founded
- SRM 1979
- BTAI 2017
- Country
- SRM United States
- BTAI United States
- Employees
- SRM N/A
- BTAI N/A
- Industry
- SRM
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- SRM
- BTAI Health Care
- Exchange
- SRM Nasdaq
- BTAI Nasdaq
- Market Cap
- SRM 9.0M
- BTAI 7.2M
- IPO Year
- SRM 2023
- BTAI 2018
- Fundamental
- Price
- SRM $0.41
- BTAI $1.88
- Analyst Decision
- SRM
- BTAI Buy
- Analyst Count
- SRM 0
- BTAI 5
- Target Price
- SRM N/A
- BTAI $42.60
- AVG Volume (30 Days)
- SRM 225.7K
- BTAI 1.2M
- Earning Date
- SRM 05-09-2025
- BTAI 03-27-2025
- Dividend Yield
- SRM N/A
- BTAI N/A
- EPS Growth
- SRM N/A
- BTAI N/A
- EPS
- SRM N/A
- BTAI N/A
- Revenue
- SRM $4,311,382.00
- BTAI $2,266,000.00
- Revenue This Year
- SRM N/A
- BTAI $105.36
- Revenue Next Year
- SRM N/A
- BTAI $46.93
- P/E Ratio
- SRM N/A
- BTAI N/A
- Revenue Growth
- SRM N/A
- BTAI 64.20
- 52 Week Low
- SRM $0.30
- BTAI $1.72
- 52 Week High
- SRM $1.85
- BTAI $49.58
- Technical
- Relative Strength Index (RSI)
- SRM 45.18
- BTAI 39.27
- Support Level
- SRM $0.38
- BTAI $1.76
- Resistance Level
- SRM $0.49
- BTAI $2.37
- Average True Range (ATR)
- SRM 0.04
- BTAI 0.28
- MACD
- SRM 0.00
- BTAI 0.03
- Stochastic Oscillator
- SRM 33.61
- BTAI 16.95
About SRM SRM Entertainment Inc.
SRM Entertainment Inc is a trusted toy and souvenir designer and developer, selling into theme parks and entertainment venues. It has developed, manufactured, and supplied the entertainment and amusement park industry with exclusive products that are often only available to consumers inside SRM's customer base venues such as Walt Disney Parks and Resorts, Universal Studios, SeaWorld, Six Flags, Great Wolf Lodge, Dollywood, and Merlin Entertainment. Its product category includes The Smurfs and Zoonicorns, Sammy Sloth, lilita Llama, kyle Koala, and Hanna Hedgehog.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.